摘要
目的:探讨沙利度胺联合肝动脉栓塞化疗治疗中晚期原发性肝癌的疗效及安全性。方法:将入组的中晚期原发性肝癌患者132例随机分治疗组70例和对照组62例。治疗组在肝动脉栓塞化疗的基础上加沙利度胺口服,剂量由100mg·d-1递增至200mg·d-1或300mg·d-1,直至出现病情进展或无法耐受不良反应止;对照组仅行肝动脉栓塞化疗。结果:治疗组和对照组的中位肿瘤进展时间(TTP)分别为7.1月和3.0月,两组差异有统计学意义(P<0.05)。治疗组和对照组的中位总生存期分别为22个月和13个月,两组差异有统计学意义(P<0.05)。6个月、12个月、18个月、24个月治疗组和对照组的生存率分别为88.6%、77.1%、65.7%、35.7%和80.6%、51.6%、30.6%、19.4%,χ2分别为2.15(P>0.100)、5.57(P<0.25)、11.31(P<0.005)、4.30(P<0.05)。主要不良反应为皮疹、便秘和嗜睡,均轻微,对症处理或减药后可缓解。结论:沙利度胺联合肝动脉栓塞化疗,能延长中晚期原发性肝癌患者生存,不良反应轻微。
Objective： To evaluate the efficacy and safety of the combination of thalidomide （TLD） with transcatheter arterial chemoembolization （TACE） in treating primary liver cancer. Methods： 132 patients of primary liver cancer were randomly divided into therapy group and control group, 70 patients of therapy group were accepted TLD for oral administration base on TACE, dose of TLD is 100 mg a day at first,and then incremental to 200 mg or 300 mg a day, until the disease progression or toxicity has become intolerable. 62 patients of control group only applied by TACE. Results： The median time to disease progression was 7.1 months for therapy group and 3.0 months for control group, it has statistical significance about two groups （ P 〈 0.05 ）. Two groups of the median overall survival time were 22 months and 13 months, it has statistical significance about two groups（P 〈0.05）. Two groups of survival rate were 88.6% 、7.1% 、65.7% 35.7% and 80.6% ,51.6% .30.6% .19.4% in 6 month 12 month 18 month 24 month. Х^2 were 2.15 （ P 〉 0. 100） 5.57 （ P 〈 0.25 ）, 11.31 （ P 〈 0. 005） ,4.30 （ P 〈 0.05 ） Adverse events included dermatitis, coprostasis and sleepiness, but was mild and reversible. Conclusion： It can prolong survival time of the patients with primary liver cancer with less toxic effects.
出处
《赣南医学院学报》
2010年第1期44-45,共2页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词
沙利度胺
肝动脉栓塞化疗
原发性肝癌
thalidomide
transcatheter arterial chemoemboliza-tion（TACE）
primary liver cancer
